z-logo
open-access-imgOpen Access
Covalent PROTACs: the best of both worlds?
Author(s) -
Neil P. Grimster
Publication year - 2021
Publication title -
rsc medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 55
ISSN - 2632-8682
DOI - 10.1039/d1md00191d
Subject(s) - covalent bond , proteolysis , chemistry , biochemistry , organic chemistry , enzyme
Covalent PROTACs combine the cutting edge research areas of targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs). This nascent field of research has already demonstrated several interesting findings, and holds an immense amount of potential to expand the druggable proteome. In this opinion, we present some of these intriguing early findings and discuss the potential advantages and disadvantages of this approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here